Tarlatamab is a bispecific T-cell engager, a class of engineered antibody molecules designed to bring immune cells and tumor cells into close contact so that the immune system can attack the cancer directly. The drug binds DLL3, a protein abundantly expressed on the surface of small cell lung cancer cells but largely absent from healthy tissues, on one side, and CD3 on T cells on the other. By bridging these two cell types, tarlatamab activates the patient’s own T cells against the tumor. The therapy has already demonstrated established clinical activity in small cell lung cancer when administered intravenously, and an approved intravenous regimen of 10 milligrams every two weeks is in clinical use. What has been missing until now is evidence that the drug can be delivered in a simpler way without sacrificing efficacy or safety.

DeLLphi-308 is the first study to evaluate subcutaneous administration of tarlatamab, and the rationale for exploring this route goes well beyond convenience. Intravenous infusions deliver the full dose into the bloodstream rapidly, producing high peak serum concentrations shortly after administration. Subcutaneous injection, by contrast, allows the drug to be absorbed gradually from the injection site, producing lower peak concentrations that appear over a delayed timeframe. For a bispecific T-cell engager, this pharmacokinetic difference matters. Rapid peaks are thought to contribute to cytokine release syndrome, a systemic inflammatory reaction that is the most characteristic toxicity of this drug class and a frequent reason for hospitalization and intensive monitoring. If subcutaneous dosing flattens the concentration curve, it could potentially reduce the incidence or severity of cytokine release syndrome while delivering the same total drug exposure.

The open-label, multicenter study enrolled patients with extensive-stage small cell lung cancer whose disease had progressed or recurred after at least one platinum-based therapy, the standard first-line backbone for this disease. In the first part of the study, investigators compared subcutaneous target doses of 10 milligrams and 15 milligrams, each administered every two weeks. Pharmacokinetic analysis showed that the 15 milligram subcutaneous dose achieved serum exposures comparable to the established intravenous regimen of 10 milligrams every two weeks. On the strength of that matching exposure, the 15 milligram dose was selected as the target dose for the second part of the study, where safety and preliminary antitumor activity were assessed in a larger group of patients.

As of the March 5, 2026 data cutoff, 40 patients had received the 15 milligram subcutaneous target dose. Treatment-related adverse events occurred in 85 percent of these patients, with 10 percent experiencing a grade 3 or higher event, a rate that investigators characterized as consistent with a manageable safety profile. The most common treatment-related toxicities were injection-site reactions, seen in half of the patients, and dysgeusia, a distortion of taste reported by 45 percent. Cytokine release syndrome occurred in 38 percent of patients, and decreased appetite in 20 percent. No grade 5, or fatal, treatment-related adverse events were recorded, an important benchmark for a therapy that mobilizes the immune system against cancer.

The pattern of cytokine release syndrome observed in the study was particularly notable. Events were predominantly grade 1, the mildest category, and no patient experienced grade 3 or higher cytokine release syndrome. Equally significant, no cytokine release event required dose interruption or discontinuation of therapy. For a drug class in which cytokine release has historically dictated step-up dosing schedules, hospitalization and careful monitoring, the ability to deliver full therapeutic doses subcutaneously with predominantly mild inflammatory events represents a meaningful advance in tolerability. The investigators attribute this favorable profile at least in part to the lower, delayed peak serum concentrations achieved with subcutaneous absorption.

Early efficacy signals were also encouraging. The preliminary objective response rate in the 15 milligram group was 30 percent, meaning roughly one in three patients with previously treated extensive-stage small cell lung cancer experienced measurable tumor shrinkage. In a disease where outcomes after platinum failure have historically been poor and where effective options remain scarce, this level of activity from a more convenient route of administration is a noteworthy finding. The investigators concluded that subcutaneous tarlatamab was well tolerated and that the observed safety profile, pharmacokinetic findings and preliminary antitumor activity, together with the potential convenience of subcutaneous administration, support further investigation of this approach.

The clinical implications extend beyond the numbers. Intravenous administration of bispecific therapies typically requires infusion suites, extended clinic visits and, in many protocols, initial hospitalization to manage the risk of cytokine release during the first doses. A subcutaneous formulation that can be injected quickly, with a safety profile dominated by low-grade events, could eventually allow treatment closer to home, reduce the logistical burden on patients who often travel long distances to specialized cancer centers, and expand access to an effective immunotherapy for populations currently underserved. For patients with extensive-stage small cell lung cancer, who frequently face limited life expectancy and heavy symptom burden, every reduction in treatment inconvenience carries real weight.

Speaking about the findings, Pedro Rocha, MD, of Hospital Universitari Vall d’Hebron in Barcelona, Spain, and primary author of the study, emphasized the pharmacokinetic achievement at the heart of the results. The findings from DeLLphi-308 suggest that a 15 milligram subcutaneous tarlatamab dose can achieve serum exposures comparable to the approved 10 milligram intravenous dosing administered every two weeks while maintaining a favorable safety profile, he noted. The predominantly low-grade cytokine release events and the preliminary antitumor activity, he added, support continued investigation of this more convenient route of administration. Updated data from the latest data cutoff were scheduled to be shared in an oral presentation at the conference on September 15, offering a fuller picture of both durability of response and long-term tolerability.

The DeLLphi-308 results arrive at a moment of rapid evolution in the treatment of small cell lung cancer, a disease long defined by its aggressiveness and its tendency to relapse after initial response to chemotherapy. Bispecific T-cell engagers targeting DLL3 have emerged as one of the most promising strategies for the previously treated setting, and the present study addresses the practical question of how such therapies can best be delivered. While the findings remain preliminary, based on 40 patients at a single data cutoff, the combination of matched drug exposure, predominantly mild cytokine release syndrome, no fatal treatment-related events and a 30 percent response rate provides a solid foundation for the next phase of development. If larger studies confirm these results, subcutaneous tarlatamab could become a template for how potent immune-engaging cancer therapies are administered, pairing the biological power of bispecific antibodies with the simplicity of an injection rather than an infusion.

Subject of Research: Subcutaneous administration of the bispecific T-cell engager tarlatamab in previously treated extensive-stage small cell lung cancer

Article Title: Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer

Article References: Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: tarlatamab, small cell lung cancer, DeLLphi-308, bispecific T-cell engager, subcutaneous immunotherapy, cytokine release syndrome, DLL3, IASLC, WCLC 2026, pharmacokinetics, extensive-stage SCLC, cancer immunotherapy